Equillium, Inc.
NASDAQ:EQBiotechnology
+$0.05 today
- Market cap
- $90.56M
- Beta
- 1.76
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.20
Volume 0.89M
Average 0.60M
EQ EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Equillium, Inc.NASDAQ: EQ
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$5.29M, compared with -$8.62M a year earlier. Trailing-twelve-month EBITDA was -$18.95M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$16.77M (+24.7%) for the fiscal year ending Dec 2026, a step up from the -194.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$5.29M-40.9% QoQ
- Last fiscal yearDec 2025
- -$22.28M-194.4% YoY
- LTMMar 2026
- -$18.95M-40.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +38.7% | — | — |
| 1 year | -194.4% | +24.7% | +219.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (22.28M) USD
- Year-over-year change
- -194.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.28M) | -194.4% |
| FY2024 | 2024-12-31 | (7.57M) | +37.6% |
| FY2023 | 2023-12-31 | (12.14M) | +80.2% |
| FY2022 | 2022-12-31 | (61.26M) | -61.6% |
| FY2021 | 2021-12-31 | (37.91M) | — |
EBITDA vs competitors
How EQ compares with its peers on the latest reported figures
- EQ's LTM Mar 2026 EBITDA of -$18.95M is the 5th highest of the 10 companies compared; the peer median is -$23.33M.
- Its year-over-year change of -40.5% is the 7th highest of 10, against a peer median of -0.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $148.02M | +264.5% | — | 223.7% | |
| LTM Mar 2026 | -$9.22M | +26.2% | — | — | |
| LTM Mar 2026 | -$10.87M | -9.4% | — | 769.0% | |
| LTM Mar 2026 | -$15.84M | +57.4% | — | 48.4% | |
| LTM Mar 2026 | -$18.95M | -40.5% | — | — | |
| LTM Mar 2026 | -$23.33M | -0.3% | — | 1017.5% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | -$34.71M | -256.5% | — | — |
| LTM Mar 2026 | -$36.2M | +34.4% | — | — | |
| LTM Mar 2026 | -$62.08M | -482.8% | — | 18634.1% | |
| LTM Mar 2026 | -$89.9M | -1211.1% | — | — | |
| Peer median (excluding EQ) | -$23.33M | -0.3% | — | 769.0% | |
Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15.76M | 36.08M | 41.1M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 116K |
| Gross Profit | 0 | 15.76M | 36.08M | 41.1M | (116K) |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | — |
| Research & Development | 26.38M | 37.55M | 37.04M | 37.43M | 12.84M |
| Selling, General & Admin | 11.41M | 17.24M | 13.57M | 11.94M | 10.79M |
| Operating Expenses | 37.79M | 77.84M | 50.61M | 49.36M | 23.63M |
| Depreciation & Amortization | 72K | 118K | 126K | 137K | 116K |
| EBITDA | (37.91M) | (61.26M) | (12.14M) | (7.57M) | (22.28M) |
| EBITDA Margin | — | -388.7% | -33.6% | -18.4% | — |
| Operating Income | (37.79M) | (62.08M) | (14.52M) | (8.27M) | (23.63M) |
| Operating Margin | — | -393.9% | -40.2% | -20.1% | — |
| Interest Income | 57K | 420K | 2.33M | 1.38M | 833K |
| Interest Expense | 1.07M | 1.05M | 491K | 0 | 0 |
| Other Income / Expenses | (1.27M) | (352K) | 1.77M | 563K | 1.24M |
| Income Before Tax | (39.05M) | (62.43M) | (12.76M) | (7.71M) | (22.4M) |
| Pre-Tax Margin | — | -396.1% | -35.3% | -18.8% | — |
| Income Tax Expense | 0 | 0 | 580K | 361K | 0 |
| Net Income | (38.98M) | (62.43M) | (13.34M) | (8.07M) | (22.4M) |
| Net Margin | — | -396.1% | -37.0% | -19.6% | — |
| EPS (Basic) | (1.35) | (3.19) | (0.38) | (0.23) | (0.39) |
| EPS (Diluted) | (1.35) | (3.19) | (0.38) | (0.23) | (0.39) |
| Weighted Avg Shares | 28.81M | 33.73M | 34.73M | 35.36M | 91.88M |
| Weighted Avg Shares (Diluted) | 28.81M | 33.73M | 34.73M | 35.36M | 91.88M |
Equillium, Inc.
NASDAQ:EQ
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.